PE20140964A1 - Antidotos anticoagulantes - Google Patents
Antidotos anticoagulantesInfo
- Publication number
- PE20140964A1 PE20140964A1 PE2013002078A PE2013002078A PE20140964A1 PE 20140964 A1 PE20140964 A1 PE 20140964A1 PE 2013002078 A PE2013002078 A PE 2013002078A PE 2013002078 A PE2013002078 A PE 2013002078A PE 20140964 A1 PE20140964 A1 PE 20140964A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- group
- refers
- cdr3
- variable domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA MOLECULA DE ANTICUERPO CONTRA DABIGATRAN QUE COMPRENDE UN DOMINIO VARIABLE DE LA CADENA PESADA CON UNA CDR1 SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID NO: 1,7,13,19,25,31,37,43,49, ENTRE OTROS, UNA CDR2 SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID NO: 2, 8, 14, 20, ENTRE OTROS, Y UNA CDR3 SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID NO: 3, 9, 15, 21, ENTRE OTRAS, Y UN DOMINIO VARIABLE DE LA CADENA LIVIANA CON UNA CDR1 SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID NO: 4, 10, 16, 22, ENTRE OTRAS, UNA CDR2 SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID NO: 5, 11, 17, 23 ENTRE OTROS, Y UNA CDR3 SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID NO: 6, 12, 18, 24, ENTRE OTRAS. DICHA MOLECULA DE ANTICUERPO ES UN ANTICUERPO POLICLONAL, UN ANTICUERPO MONOCLONAL, ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO DE FABRICACION DE DICHA MOLECULA. SIENDO UTIL EN LA PREVENCION DE EFECTOS SECUNDARIOS DE LA TERAPIA CON ANTICOAGULANTES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161469207P | 2011-03-30 | 2011-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20140964A1 true PE20140964A1 (es) | 2014-08-17 |
Family
ID=45876804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013002078A PE20140964A1 (es) | 2011-03-30 | 2012-03-27 | Antidotos anticoagulantes |
Country Status (22)
Country | Link |
---|---|
US (2) | US8821871B2 (es) |
EP (1) | EP2691156A1 (es) |
JP (1) | JP2014515740A (es) |
KR (1) | KR20140009437A (es) |
CN (1) | CN103476459A (es) |
AP (1) | AP2013007046A0 (es) |
AR (1) | AR085758A1 (es) |
BR (1) | BR112013025031A2 (es) |
CA (1) | CA2827787A1 (es) |
CL (1) | CL2013002551A1 (es) |
CO (1) | CO6771448A2 (es) |
EA (1) | EA201301090A1 (es) |
EC (1) | ECSP13012997A (es) |
IL (1) | IL227653A0 (es) |
MA (1) | MA34978B1 (es) |
MX (1) | MX2013011092A (es) |
PE (1) | PE20140964A1 (es) |
SG (1) | SG193552A1 (es) |
TN (1) | TN2013000388A1 (es) |
TW (1) | TW201302796A (es) |
UY (1) | UY33994A (es) |
WO (1) | WO2012130834A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2865068T3 (es) | 2011-01-14 | 2021-10-14 | Univ California | Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos |
UA116336C2 (uk) | 2011-11-29 | 2018-03-12 | Перосфіе Фармасьютікалз Інк. | Агенти, реверсуючі дію антикоагулянтів |
US10100123B2 (en) | 2013-06-06 | 2018-10-16 | Pierre Fabre Medicament | Anti-C10orf54 antibodies and uses thereof |
MX368625B (es) * | 2013-07-30 | 2019-10-08 | Janssen Sciences Ireland Uc | Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales. |
KR101523503B1 (ko) * | 2013-09-17 | 2015-05-29 | 강원대학교산학협력단 | 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물 |
EP3060583A1 (en) | 2013-10-25 | 2016-08-31 | Boehringer Ingelheim International GmbH | Anticoagulant antidotes |
EP2980218A1 (en) * | 2014-07-30 | 2016-02-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors |
WO2019210270A2 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | In vivo gene therapy using delivery of a lentiviral gene construct |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ATE151113T1 (de) | 1992-01-23 | 1997-04-15 | Merck Patent Gmbh | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
DK0701571T3 (da) | 1993-06-03 | 1997-09-15 | Therapeutic Antibodies Inc | Antistoffragmenter til terapi |
AT404357B (de) | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
DE19605126A1 (de) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
US6440417B1 (en) | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
US20040010134A1 (en) | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
EP2390268B1 (en) | 2002-11-08 | 2017-11-01 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
CA2697583C (en) | 2007-09-28 | 2016-04-12 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
AU2010288601A1 (en) * | 2009-08-24 | 2012-02-02 | Boehringer Ingelheim International Gmbh | Emergency interventions of active charcoal with dabigatran etexilate overdosing |
AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
-
2012
- 2012-03-27 PE PE2013002078A patent/PE20140964A1/es not_active Application Discontinuation
- 2012-03-27 SG SG2013070719A patent/SG193552A1/en unknown
- 2012-03-27 KR KR1020137025877A patent/KR20140009437A/ko not_active Application Discontinuation
- 2012-03-27 JP JP2014501575A patent/JP2014515740A/ja not_active Ceased
- 2012-03-27 MA MA36273A patent/MA34978B1/fr unknown
- 2012-03-27 MX MX2013011092A patent/MX2013011092A/es not_active Application Discontinuation
- 2012-03-27 CA CA2827787A patent/CA2827787A1/en not_active Abandoned
- 2012-03-27 AP AP2013007046A patent/AP2013007046A0/xx unknown
- 2012-03-27 WO PCT/EP2012/055397 patent/WO2012130834A1/en active Application Filing
- 2012-03-27 BR BR112013025031A patent/BR112013025031A2/pt not_active IP Right Cessation
- 2012-03-27 EA EA201301090A patent/EA201301090A1/ru unknown
- 2012-03-27 EP EP12710300.0A patent/EP2691156A1/en not_active Withdrawn
- 2012-03-27 CN CN2012800157134A patent/CN103476459A/zh active Pending
- 2012-03-28 US US13/432,296 patent/US8821871B2/en active Active
- 2012-03-29 AR ARP120101085A patent/AR085758A1/es unknown
- 2012-03-29 TW TW101111195A patent/TW201302796A/zh unknown
- 2012-03-29 UY UY0001033994A patent/UY33994A/es unknown
-
2013
- 2013-07-25 IL IL227653A patent/IL227653A0/en unknown
- 2013-09-05 CL CL2013002551A patent/CL2013002551A1/es unknown
- 2013-09-20 CO CO13224736A patent/CO6771448A2/es unknown
- 2013-09-26 TN TNP2013000388A patent/TN2013000388A1/fr unknown
- 2013-10-25 EC ECSP13012997 patent/ECSP13012997A/es unknown
-
2014
- 2014-07-22 US US14/337,357 patent/US20140377265A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO6771448A2 (es) | 2013-10-15 |
MA34978B1 (fr) | 2014-03-01 |
SG193552A1 (en) | 2013-11-29 |
CL2013002551A1 (es) | 2014-02-14 |
NZ613543A (en) | 2015-07-31 |
ECSP13012997A (es) | 2013-12-31 |
UY33994A (es) | 2012-09-28 |
MX2013011092A (es) | 2013-12-06 |
US8821871B2 (en) | 2014-09-02 |
EA201301090A1 (ru) | 2014-05-30 |
IL227653A0 (en) | 2013-09-30 |
BR112013025031A2 (pt) | 2017-08-01 |
AP2013007046A0 (en) | 2013-08-31 |
TN2013000388A1 (en) | 2015-01-20 |
AR085758A1 (es) | 2013-10-23 |
WO2012130834A1 (en) | 2012-10-04 |
CA2827787A1 (en) | 2012-10-04 |
CN103476459A (zh) | 2013-12-25 |
TW201302796A (zh) | 2013-01-16 |
US20120276123A1 (en) | 2012-11-01 |
JP2014515740A (ja) | 2014-07-03 |
KR20140009437A (ko) | 2014-01-22 |
EP2691156A1 (en) | 2014-02-05 |
US20140377265A1 (en) | 2014-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140964A1 (es) | Antidotos anticoagulantes | |
CL2018001177A1 (es) | Anticuerpos vinculados especificamente a pd-1 y sus usos. | |
PE20180499A1 (es) | Anticuerpos de union a tau | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
UA110470C2 (ru) | Антидот антикоагулянта | |
CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
PE20190208A1 (es) | Anticuerpos que reconocen tau | |
PE20150002A1 (es) | Anticuerpos anti-fcrn | |
EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
MX341958B (es) | Anticuerpos contra el il33r humano y usos de los mismos. | |
AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
GT201400045A (es) | Anticuerpo anti-abtcr | |
PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
AR084315A1 (es) | Anticuerpos anti-notch1 | |
EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
EA201491214A1 (ru) | Композиции и способы применения антител, нацеленных на фактор p | |
BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
ES2722824T3 (es) | Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) | |
ES2664972T3 (es) | Moléculas de unión anti-Psl de Pseudomonas y usos de las mismas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |